KR102408814B1 - 루푸스를 치료하기 위한 화합물 및 방법 - Google Patents

루푸스를 치료하기 위한 화합물 및 방법 Download PDF

Info

Publication number
KR102408814B1
KR102408814B1 KR1020197011411A KR20197011411A KR102408814B1 KR 102408814 B1 KR102408814 B1 KR 102408814B1 KR 1020197011411 A KR1020197011411 A KR 1020197011411A KR 20197011411 A KR20197011411 A KR 20197011411A KR 102408814 B1 KR102408814 B1 KR 102408814B1
Authority
KR
South Korea
Prior art keywords
compound
groups
dihydro
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197011411A
Other languages
English (en)
Korean (ko)
Other versions
KR20190060791A (ko
Inventor
피오나 로렌 스콧
크리스틴 알. 테일러 메도우스
로버트 피치
Original Assignee
리셉토스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리셉토스 엘엘씨 filed Critical 리셉토스 엘엘씨
Publication of KR20190060791A publication Critical patent/KR20190060791A/ko
Application granted granted Critical
Publication of KR102408814B1 publication Critical patent/KR102408814B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197011411A 2016-09-29 2017-09-28 루푸스를 치료하기 위한 화합물 및 방법 Active KR102408814B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662401762P 2016-09-29 2016-09-29
US62/401,762 2016-09-29
PCT/US2017/054053 WO2018064356A1 (en) 2016-09-29 2017-09-28 Compounds and methods for treating lupus

Publications (2)

Publication Number Publication Date
KR20190060791A KR20190060791A (ko) 2019-06-03
KR102408814B1 true KR102408814B1 (ko) 2022-06-14

Family

ID=60043386

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197011411A Active KR102408814B1 (ko) 2016-09-29 2017-09-28 루푸스를 치료하기 위한 화합물 및 방법

Country Status (6)

Country Link
US (1) US11278526B2 (https=)
EP (1) EP3518922B1 (https=)
JP (1) JP7086945B2 (https=)
KR (1) KR102408814B1 (https=)
CA (1) CA3038106A1 (https=)
WO (1) WO2018064356A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630738B1 (en) * 2017-05-22 2023-07-19 Egis Gyógyszergyár Zrt. Process for the production of ozanimod
AR116479A1 (es) * 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
EP3947363A4 (en) * 2019-03-29 2023-01-04 Receptos Llc SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS
CN116332794B (zh) * 2021-12-24 2024-10-15 上海合全药物研发有限公司 一种芳基腈类化合物的制备方法
US12565492B2 (en) 2024-08-09 2026-03-03 Triana Biomedicines, Inc. Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008074821A1 (en) 2006-12-21 2008-06-26 Glaxo Group Limited Indole derivatives as s1p1 receptor agonists
WO2015066515A1 (en) * 2013-11-01 2015-05-07 Receptos, Inc. Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0612028A2 (pt) 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
RU2009115963A (ru) 2006-09-29 2010-11-10 Новартис АГ (CH) Производные оксадиазола, обладающие противовоспалительными и иммунодепрессантными свойствами
SI2291080T1 (sl) 2008-05-14 2015-11-30 The Scripps Research Institute Novi modulatorji sfingosinskih fosfatnih receptorjev
EA024801B1 (ru) * 2009-11-13 2016-10-31 Рецептос Ллк Селективные модуляторы рецептора сфингозин-1-фосфата

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008074821A1 (en) 2006-12-21 2008-06-26 Glaxo Group Limited Indole derivatives as s1p1 receptor agonists
WO2015066515A1 (en) * 2013-11-01 2015-05-07 Receptos, Inc. Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
British Journal of Pharmacology, 173(11), 1778-1792, 2016.*
F1000Prime Reports, 6:109/1-7, 2014.

Also Published As

Publication number Publication date
KR20190060791A (ko) 2019-06-03
JP7086945B2 (ja) 2022-06-20
EP3518922B1 (en) 2026-02-11
US20190224172A1 (en) 2019-07-25
US11278526B2 (en) 2022-03-22
WO2018064356A1 (en) 2018-04-05
JP2019529487A (ja) 2019-10-17
CA3038106A1 (en) 2018-04-05
EP3518922A1 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
KR102408814B1 (ko) 루푸스를 치료하기 위한 화합물 및 방법
TWI817968B (zh) 作為C5aR抑制劑之經二芳基取代之5,5-稠合環化合物
TWI813570B (zh) 作為C5a抑制劑之5-5稠合環
US11207301B2 (en) Sphingosine 1 phosphate receptor agonists for neuroprotection
JP5988379B2 (ja) スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
TWI789470B (zh) 作為C5aR抑制劑之經二芳基取代之6,5-稠合環化合物
JP5908455B2 (ja) Ｃｇｒｐ受容体アンタゴニスト
JP2021519794A (ja) 縮合二環式Ｃ５ａＲアンタゴニストのプロドラッグ
KR20120102704A (ko) 선택적인 스핑고신 1 포스페이트 수용체 조절자 및 카이랄 합성 방법
JP2006528980A (ja) Ｓ１ｐ受容体作働薬としての３−（２−アミノ−１−アザシクロ）−５−アリール−１，２，４−オキサジアゾール類
JP2022065035A (ja) α５含有ＧＡＢＡＡ受容体アゴニストによる神経変性および神経精神障害における認知症状および気分症状の処置
EP2853532B1 (en) 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
US10538482B2 (en) Adamantane and memantine derivatives as peripheral NMDA receptor antagonists
CN110234643A (zh) RORγ调节剂及其用途
US12274694B2 (en) Dizocilpine derivatives as peripheral NMDA receptor antagonists
TWI537251B (zh) Ｆｐｒ１拮抗劑的衍生物及其用途
US10669266B2 (en) Oxadiazole inhibitors of HIPK2 for treating kidney fibrosis
CN110177775A (zh) RORγ调节剂及其用途
RU2780322C2 (ru) 5-5 КОНДЕНСИРОВАННЫЕ КОЛЬЦА КАК ИНГИБИТОРЫ С5а
TW201534322A (zh) Ｆｐｒ１拮抗劑的衍生物及其用途（一）

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190419

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200812

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211001

Patent event code: PE09021S01D

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20211020

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20220103

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220602

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220609

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220610

End annual number: 3

Start annual number: 1

PG1601 Publication of registration